Keltjens previously served as CEO at Medtronic CryoCath , AngioDynamics and held a number of senior leadership positions at Cordis.

He will focus on the commercialization of Endosense’s proprietary TactiCath, a contact-force sensing ablation catheter.

Endosense is enrolling patients for its Toccastar investigational device exemption (IDE) clinical trial.

The study results will be used to fill a premarket approval (PMA) application in order to receive the US Food and Drug Administration (FDA) clearance for its contact-force sensing ablation catheter.

Endosense chairman Jan Egberts said the company is creating a breakthrough in the field of catheter ablation with its TactiCath contact-force sensing catheter, which gives physicians therapeutic information to improve procedure safety and effectiveness.

"We believe this new technology will have a profound, positive impact on clinical practice, benefitting both patients and physicians," Egberts said.